

REMARKS

The Examiner has required restriction between:

GROUP I - claims 1-45, drawn to a method of determining the molecular flux rates of a plurality of proteins in all or a portion of the proteome of a cell, tissue or organism.

GROUP II - claims 46-47, drawn to rights to drugs or other therapeutic agents.

Applicant hereby elects **Group I**, claims 1-45 for continued examination, without traverse.

The Examiner has further required election of a single and specific species for each of the following species:

isotope labels (e.g., claims 1, 13-16, 26);

organic metabolite or organic metabolite precursors to said cell (e.g., claims 1, 24, 25, 35;

diagnostic or therapeutic agents (e.g., claims 41, 42, 46-47)

With regards to the requirement for an election of a specific species of diagnostic or therapeutic agent, Applicant is unclear on how the elected group of claims is “directed to more than more species of the generic invention”. The Examiner has indicated that claims 41, 42, and 46-47 are exemplary claims presenting specific species of the generic species “diagnostic or therapeutic agents”. However, Applicant has not been able to clearly identify specific species within the exemplary claims. In the absence of clear delineation of species, Applicant presumes that the Examiner is referring to “diagnostic agents” and “therapeutic agents” as the separate specific species for election. Applicant’s election is predicted on this assumption.

Accordingly, Applicant hereby elects the following species:

isotope label: ^2H ;

organic metabolite or organic metabolite precursor to said cell: H_2O ;

diagnostic or therapeutic agent: **therapeutic agent**.

Applicant expressly reserves the right under 35 U.S.C. § 121 to file a divisional application directed to the nonelected subject matter.

CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No.: 03-1952** referencing **416272003800**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated:: June 3, 2008

Respectfully submitted,

By 

Michael R. Ward

Registration No.: 38,651
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
415.268.6237